Thesalonica Hilliard
Family · Lemon Grove, CANPI 1861956724
Payments from drug & device makers
Across 123 payments — averaging $32.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$723
- Abbott$709
- AstraZeneca$521
- Madrigal Pharmaceuticals$379
- Dexcom, Inc.$313
- Lilly USA, LLC$260
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,982100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $723 |
| Abbott | 22 | $709 |
| AstraZeneca | 7 | $521 |
| Madrigal Pharmaceuticals | 14 | $379 |
| Dexcom, Inc. | 6 | $313 |
| Lilly USA, LLC | 8 | $260 |
| Boston Scientific | 2 | $216 |
| Exact Sciences | 7 | $151 |
| Hologic Sales And Service, LLC | 4 | $105 |
| Scilex Pharmaceuticals Inc. | 5 | $96 |
| Tandem Diabetes Care, Inc. | 1 | $66 |
| Cranial Technologies, Inc | 4 | $65 |
| Gilead | 2 | $63 |
| Amgen | 3 | $57 |
| Pfizer | 2 | $36 |
| AbbVie | 1 | $34 |
| Bayer | 2 | $28 |
| Boehringer Ingelheim | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $22 |
| Phadia US Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Insulet Corporation | 1 | $13 |
| GSK | 1 | $13 |
| Bristol Myers Squibb | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$349
- WATCHMAN Access System$216
- DEXCOM G7 GSS (161)$151
- DEXCOM STELO GLUCOSE BIOSENSOR$151
- GALLANT$148
- REZDIFFRA$147
- FREESTYLE LIBRE 3$144
- Wegovy$125
- RYBELSUS$121
How this compares
$3,982 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 117 | $124,263 |
| FarxigaDapagliflozin Propanediol | 117 | $123,468 |
| JanuviaSitagliptin Phosphate | 52 | $66,768 |
| OzempicSemaglutide | 56 | $62,497 |
| TrulicityDulaglutide | 26 | $23,813 |
| RybelsusSemaglutide | 18 | $22,031 |
| EliquisApixaban | 15 | $16,325 |
| EntrestoSacubitril/Valsartan | 13 | $8,502 |
| RestasisCyclosporine | 12 | $7,250 |
| BaqsimiGlucagon | 11 | $5,408 |
| Rosuvastatin Calcium | 117 | $3,356 |
| Atorvastatin Calcium | 340 | $3,014 |
| Losartan Potassium | 311 | $2,947 |
| Metoprolol Succinate | 160 | $2,305 |
| Metformin Hcl | 287 | $2,181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $24 | $124,263117 claims |
| AstraZenecaFarxiga | $521 | $123,468117 claims |
| Novo NordiskOzempic, Rybelsus | $723 | $84,52874 claims |
| MerckJanuvia | $16 | $66,76852 claims |
| Lilly USA, LLCTrulicity, Baqsimi | $260 | $29,22137 claims |
| PfizerEliquis | $36 | $16,32515 claims |
| AbbVieRestasis | $34 | $7,25012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.
Other family in Lemon Grove
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.